:: Library Catalog

Salvato in:

Dettagli Bibliografici
Autore principale:	Hanamura, Satoshi
Natura:	Recurso digital
Lingua:	inglese
Pubblicazione:	Zenodo 2023
Soggetti:	0-Sphere model
Accesso online:	https://doi.org/10.5281/zenodo.17764952
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Transition Theory of An Electron Traveling from Uncertain to Causal Basis
di: Hanamura, Satoshi
Pubblicazione: (2019)

New horizons in the pharmacological management of venous thromboembolism
di: Andreas Verstraete, et al.
Pubblicazione: (2025)

News on sickle cell disease: Heme‐driven disordered erythropoiesis
di: Francesca Vinchi
Pubblicazione: (2024)

New approaches in gene therapy for sickle cell disease, moving in vivo
di: David G. Kent
Pubblicazione: (2024)

Correction to “New approaches in gene therapy for sickle cell disease, moving in vivo”
Pubblicazione: (2024)

Models for the marrow: A comprehensive review of AI‐based cell classification methods and malignancy detection in bone marrow aspirate smears
di: Tabita Ghete, et al.
Pubblicazione: (2024)

Issue Information
Pubblicazione: (2025)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
di: Raúl Córdoba, et al.
Pubblicazione: (2026)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
di: Anna Ossami Saidy, et al.
Pubblicazione: (2025)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
di: Enrico Attardi, et al.
Pubblicazione: (2024)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
di: Henri C. Hupe, et al.
Pubblicazione: (2025)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
di: Jan‐Niklas Eckardt, et al.
Pubblicazione: (2025)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
di: Konstanze Döhner, et al.
Pubblicazione: (2025)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
di: David A. Sallman, et al.
Pubblicazione: (2025)

TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis
di: Harmony C. Ketchum, et al.
Pubblicazione: (2025)

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second‐line therapy in pediatric chronic myeloid leukemia
di: Stephanie Sembill, et al.
Pubblicazione: (2026)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
di: Uwe Platzbecker, et al.
Pubblicazione: (2025)

HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
di: Sotiroula Chatzimatthaiou, et al.
Pubblicazione: (2025)

MMS22L is a novel key actor of normal and pathological erythropoiesis
di: Elia Colin, et al.
Pubblicazione: (2025)

Correction to “Quality of vitamin K antagonist treatment during the last year of life”
Pubblicazione: (2025)

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
di: Daniel Mazza Matos
Pubblicazione: (2026)

Publication Only
Pubblicazione: (2025)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
di: Cristina A. Tentori, et al.
Pubblicazione: (2024)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
di: Rebeqa Gunnarsson, et al.
Pubblicazione: (2025)

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
di: Mwanasha H. Merrill, et al.
Pubblicazione: (2025)

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B‐cell lymphoma
di: André Airosa Pardal, et al.
Pubblicazione: (2025)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
di: Martijn W. C. Verbeek, et al.
Pubblicazione: (2025)

Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation
di: Suzana da Silva‐Benedito, et al.
Pubblicazione: (2026)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
di: Thomas C. Wiemers, et al.
Pubblicazione: (2026)

Dynamic evolution of TCF3‐PBX1 leukemias at the single‐cell level under chemotherapy pressure
di: Mira Kusterer, et al.
Pubblicazione: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Pubblicazione: (2025)

Issue Information
Pubblicazione: (2024)

APL‐like subset within NPM1 ‐mutated AML: A distinct immunophenotype correlating with early vascular complications
di: Francesco Mannelli, et al.
Pubblicazione: (2026)

Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation
di: Konradin F. Müskens, et al.
Pubblicazione: (2024)

Can health inequalities in sickle cell disease be addressed through novel therapies?
di: Stephen P. Hibbs, et al.
Pubblicazione: (2025)

Issue Information
Pubblicazione: (2024)

Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
di: Shoshana Burke, et al.
Pubblicazione: (2025)

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells
di: Romane Durand, et al.
Pubblicazione: (2024)

Neuroinflammatory changes in acute myeloid leukemia: Evidence for blood–brain barrier disruption and glial activation
di: Marta Febo, et al.
Pubblicazione: (2026)

Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study
di: Marcus Hentrich, et al.
Pubblicazione: (2024)